niacinamide has been researched along with Degenerative Diseases, Central Nervous System in 19 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This review provides renewed insights regarding the clinical utility and benefits of NAD+ precursors, namely nicotinamide (NAM), nicotinic acid (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), in attenuating NAD+ decline and phenotypic characterization of age-related disorders, including metabolic, cardiovascular and neurodegenerative diseases." | 5.41 | Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders. ( Braidy, N; Helman, T, 2023) |
| " Most studies indicated that the NAD+ precursors NAM, NR, nicotinamide mononucleotide (NMN), and to a lesser extent NAD+ and NADH had a favourable outcome on several age-related disorders associated with the accumulation of chronic oxidative stress, inflammation and impaired mitochondrial function." | 5.05 | NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. ( Braidy, N; Liu, Y, 2020) |
| " However, nicotinamide offers cellular protection in a specific concentration range, with dosing outside of this range leading to detrimental effects." | 2.72 | Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders. ( Maiese, K, 2021) |
| "Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline." | 1.62 | Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction. ( Brautaset, R; Burgess, RW; Cimaglia, G; Crowston, JG; Domínguez-Vicent, A; Ellis, SA; Fuerst, PG; Jöe, M; Jóhannesson, G; Kokkali, E; Kolko, M; Lardner, E; Morgan, JE; Otmani, A; Rho, S; Sun, S; Tribble, JR; Venkataraman, AP; Vohra, R; Votruba, M; Williams, PA, 2021) |
| "Most human neurodegenerative diseases have a number of common features, including adult onset, progressive degeneration of selected neuronal populations and formation of abnormal protein aggregates." | 1.32 | Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. ( Feany, MB; Ghosh, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 11 (57.89) | 2.80 |
| Authors | Studies |
|---|---|
| Ghazanfari, N | 1 |
| van Waarde, A | 1 |
| Doorduin, J | 1 |
| Sijbesma, JWA | 1 |
| Kominia, M | 1 |
| Koelewijn, M | 1 |
| Attia, K | 1 |
| Willemsen, ATM | 1 |
| Visser, TJ | 1 |
| Heeres, A | 1 |
| Dierckx, RAJO | 1 |
| de Vries, EFJ | 1 |
| Elsinga, PH | 1 |
| Talavera Andújar, B | 1 |
| Aurich, D | 1 |
| Aho, VTE | 1 |
| Singh, RR | 1 |
| Cheng, T | 1 |
| Zaslavsky, L | 1 |
| Bolton, EE | 1 |
| Mollenhauer, B | 1 |
| Wilmes, P | 1 |
| Schymanski, EL | 1 |
| Helman, T | 2 |
| Braidy, N | 3 |
| Li, X | 1 |
| Yang, H | 1 |
| Jin, H | 1 |
| Turkez, H | 1 |
| Ozturk, G | 1 |
| Doganay, HL | 1 |
| Zhang, C | 1 |
| Nielsen, J | 1 |
| Uhlén, M | 1 |
| Borén, J | 1 |
| Mardinoglu, A | 1 |
| Liu, Y | 1 |
| Orlandi, I | 1 |
| Vai, M | 1 |
| Fragola, G | 1 |
| Mabb, AM | 1 |
| Taylor-Blake, B | 1 |
| Niehaus, JK | 1 |
| Chronister, WD | 1 |
| Mao, H | 1 |
| Simon, JM | 1 |
| Yuan, H | 1 |
| Li, Z | 1 |
| McConnell, MJ | 1 |
| Zylka, MJ | 1 |
| Mehmel, M | 1 |
| Jovanović, N | 1 |
| Spitz, U | 1 |
| Maiese, K | 1 |
| Tribble, JR | 1 |
| Otmani, A | 1 |
| Sun, S | 1 |
| Ellis, SA | 1 |
| Cimaglia, G | 1 |
| Vohra, R | 1 |
| Jöe, M | 1 |
| Lardner, E | 1 |
| Venkataraman, AP | 1 |
| Domínguez-Vicent, A | 1 |
| Kokkali, E | 1 |
| Rho, S | 1 |
| Jóhannesson, G | 1 |
| Burgess, RW | 1 |
| Fuerst, PG | 1 |
| Brautaset, R | 1 |
| Kolko, M | 1 |
| Morgan, JE | 1 |
| Crowston, JG | 1 |
| Votruba, M | 1 |
| Williams, PA | 1 |
| Gao, Y | 1 |
| Martin, NI | 1 |
| van Haren, MJ | 1 |
| Ieraci, A | 2 |
| Herrera, DG | 2 |
| Klimova, N | 1 |
| Kristian, T | 1 |
| Harrington, M | 1 |
| Burgess, S | 1 |
| Echeverria, V | 1 |
| Ullah, N | 1 |
| Lee, HY | 1 |
| Naseer, MI | 1 |
| Ullah, I | 1 |
| Suh, JW | 1 |
| Kim, MO | 1 |
| Ghosh, S | 1 |
| Feany, MB | 1 |
| Belenky, P | 1 |
| Bogan, KL | 1 |
| Brenner, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacinamide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders.
Topics: Aging; Dietary Supplements; Humans; NAD; Neurodegenerative Diseases; Niacinamide; Nicotinamide Monon | 2023 |
Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders.
Topics: Aging; Dietary Supplements; Humans; NAD; Neurodegenerative Diseases; Niacinamide; Nicotinamide Monon | 2023 |
Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders.
Topics: Aging; Dietary Supplements; Humans; NAD; Neurodegenerative Diseases; Niacinamide; Nicotinamide Monon | 2023 |
Importance of NAD+ Anabolism in Metabolic, Cardiovascular and Neurodegenerative Disorders.
Topics: Aging; Dietary Supplements; Humans; NAD; Neurodegenerative Diseases; Niacinamide; Nicotinamide Monon | 2023 |
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Topics: Aging; Animals; Humans; Inflammation; Mice; NAD; Neurodegenerative Diseases; Niacinamide; Nicotinami | 2020 |
Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
Topics: Aging; Animals; Betacoronavirus; Biological Availability; Cardiovascular Diseases; Coronavirus Infec | 2020 |
Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.
Topics: Animals; Humans; Metabolic Diseases; Neurodegenerative Diseases; Niacinamide; Oxidative Stress; Sign | 2021 |
Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target.
Topics: Enzyme Inhibitors; Humans; Metabolic Diseases; Neoplasms; Neurodegenerative Diseases; Niacinamide; N | 2021 |
Multi-targeted Effect of Nicotinamide Mononucleotide on Brain Bioenergetic Metabolism.
Topics: Animals; Brain; Humans; Hydrolases; Mitochondria; NAD; Neurodegenerative Diseases; Niacinamide; Nico | 2019 |
Raf inhibitors as therapeutic agents against neurodegenerative diseases.
Topics: Animals; Benzenesulfonates; Brain; Disease Models, Animal; Drug Design; Encephalitis; Humans; Inflam | 2010 |
NAD+ metabolism in health and disease.
Topics: ADP Ribose Transferases; ADP-ribosyl Cyclase; Aging; Animals; Candida glabrata; Candidiasis; Humans; | 2007 |
1 trial available for niacinamide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
The acute effect of different NAD
Topics: Humans; Metabolic Diseases; NAD; Neurodegenerative Diseases; Niacin; Niacinamide; Nicotinamide Monon | 2023 |
10 other studies available for niacinamide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Pharmacokinetic Modeling of [
Topics: Animals; Benzazepines; Brain; Carrier Proteins; Histamine; Neurodegenerative Diseases; Niacinamide; | 2022 |
Studying the Parkinson's disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: a pilot study.
Topics: Aged; Alanine; Betaine; Cheminformatics; Exposome; Humans; Metabolome; Metabolomics; Neurodegenerati | 2022 |
Assays for Monitoring the Effects of Nicotinamide Supplementation on Mitochondrial Activity in Saccharomyces cerevisiae.
Topics: Aging; Cell Respiration; Dietary Supplements; Membrane Potential, Mitochondrial; Mitochondria; Mitoc | 2020 |
Deletion of Topoisomerase 1 in excitatory neurons causes genomic instability and early onset neurodegeneration.
Topics: Animals; Apoptosis; Cerebral Cortex; DNA Damage; DNA Topoisomerases, Type I; Genomic Instability; Hi | 2020 |
Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction.
Topics: Animals; Disease Models, Animal; Glaucoma; Humans; Neurodegenerative Diseases; Neuroprotection; Niac | 2021 |
Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.
Topics: Animals; Animals, Newborn; Benzamides; Caspase 3; Cell Death; Central Nervous System Depressants; Ce | 2018 |
Reversing neurodegenerative hearing loss.
Topics: Animals; Disease Models, Animal; Hearing Loss; Humans; Mice; Mice, Knockout; NAD; Neurodegenerative | 2015 |
Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain.
Topics: Alkylating Agents; Animals; Apoptosis; bcl-2-Associated X Protein; Brain; Caspase 3; Cell Survival; | 2011 |
Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
Topics: Animals; Apoptosis; Ataxin-1; Ataxin-3; Ataxins; Brain; Brain Chemistry; Disease Models, Animal; Dro | 2004 |
Nicotinamide protects against ethanol-induced apoptotic neurodegeneration in the developing mouse brain.
Topics: Animals; Apoptosis; Brain; Central Nervous System Depressants; Ethanol; Female; Fetal Alcohol Spectr | 2006 |